Research provides new hope for those suffering from Crohn's disease

Researchers from the Hotchkiss Brain Institute (HBI) and the Snyder Institute for Chronic Diseases at the University of Calgary's Faculty of Medicine have discovered a pathway that may contribute to the symptoms related to Crohn's disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease (IBD). This research is a major milestone in developing future drug therapies for those living with these debilitating disorders.

The digestive process is complex. To coordinate the many functions involved in digestion, the gut has its own set of (neurons), often called the "second brain". Crohn's disease is characterized by inflammation in the gut, leading to damage or death of millions of these neurons lining the . As a consequence, patients are left with a host of debilitating symptoms including abdominal pain and numerous disruptive digestive conditions. Using translatable animal models, these new research findings have identified "pannexins" as molecules that mediate gut and, as such, may allow for the development of new treatments to prevent it.

"Our work identifies a critical mechanism of neuron death in intestinal inflammation that appears relevant to IBD," says Brian Gulbransen, PhD, the study's lead author and a postdoctoral fellow at the University of Calgary's HBI. "We used animal models of to show that blocking the "pannexins" was able to prevent gut neuron death. Interestingly, we found the "pannexins" involved in the death of mouse gut neurons are also present in neurons."

Canada has one of the highest incidences of IBD in the world and it affects over 200,000 Canadians. Previously, researchers could not identify the cause of gut neuron death, and therefore no therapeutic strategies exist to prevent it. Current IBD treatment options are limited to controlling inflammation, which frequently leaves patients to still suffer with chronic gut dysfunction. "Although our research will not cure IBD, these findings could lead to developing therapeutics for the debilitating symptoms in those who suffer from Crohn's disease," says Keith Sharkey PhD, the senior author of the paper, the Crohn's & Colitis Foundation of Canada Chair in IBD Research, and member of the Snyder Institute and Deputy Director of the HBI, at the University of Calgary.

This study is published in the April print edition of the prestigious journal Nature Medicine (available online March 19th).

Related Stories

Promising probiotic treatment for inflammatory bowel disease

date Jan 20, 2010

Bacteria that produce compounds to reduce inflammation and strengthen host defences could be used to treat inflammatory bowel disease (IBD). Such probiotic microbes could be the most successful treatment for IBD to date, ...

Inflammatory bowel disease emerges as a global disease

date Jan 04, 2012

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastro ...

Recommended for you

Severe asthma fails to respond to mainstay treatment

date Jun 29, 2015

The immune response that occurs in patients with severe asthma is markedly different than what occurs in milder forms of the lung condition, according to researchers from the University of Pittsburgh School ...

New hope for patients with chronic wounds

date Jun 29, 2015

Most wounds clear up by themselves, but some fail to heal and become chronic. An international team of researchers led from Karolinska Institutet, now unveil the important role of so-called microRNAs in regulating skin wound ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.